Estimating the cost related to surveillance of colorectal cancer in a French population.
Fiche publication
Date publication
octobre 2009
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent, Pr BINQUET Christine, Pr LEJEUNE Catherine, Pr QUANTIN Catherine
Tous les auteurs :
Lejeune C, Binquet C, Bonnetain F, Mahboubi A, Abrahamowicz M, Moreau T, Raikou M, Bedenne L, Quantin C, Bonithon-Kopp C
Lien Pubmed
Résumé
Little is known about costs related to the surveillance of patients that have undergone curative resection of colorectal cancer. The aim of this study was to calculate the observed surveillance costs for 385 patients followed-up over a 3-year period, to estimate surveillance costs if French guidelines are respected, and to identify the determinants related to surveillance costs to derive a global estimation for France, using a linear mixed model. The observed mean surveillance cost was 713. If French recommendations were strictly applied, the estimated mean cost would vary between 680 and 1,069 according to the frequency of abdominal ultrasound. The predicted determinants of cost were: age, recurrence, duration of surveillance since diagnosis, and adjuvant treatments. For France, the surveillance cost represented 4.4% of the cost of colorectal cancer management. The cost of surveillance should now be balanced with its effectiveness and compared with surveillance alternatives.
Référence
Eur J Health Econ. 2009 Oct;10(4):409-19